Previous 10 | Next 10 |
Amryt Pharma plc - Key Dates for AIM Delisting DUBLIN, Ireland, and Boston MA, January 6 , 2022 , Amryt Pharma plc (Nasdaq: AMYT, AIM: AMYT) (“ Amryt ” or the “ Company ...
The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa ® (oral octreotide) in Acromegaly P atients DUBLIN, Ireland, and Boston MA, January 4 , 202 2 , Amryt (...
Amryt Pharma is developing and delivering innovative medicines for rare and debilitating conditions. The Company has acquired three companies since formation, and has commercialized three medicines. The Company also has a significant development pipeline. For further details...
Amryt Pharma (NASDAQ:AMYT) ADRs have lost ~6.8% in the pre-market after the company announced a prolonged duration for the regulatory review of Oleogel-S10 for the treatment of cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (“EB”). The...
Amryt Provides Update on Regulatory Review Process for Oleogel-S10 FDA PDUFA goal date extended by three months to February 28, 2022 EMA CHMP opinion now expected in January 2022 DUBLIN, Ireland, and Boston MA, November 23 , 2021, Am...
ReTo Eco-Solutions (NASDAQ:RETO) -18%. Aurora Innovation (NASDAQ:AUR) -18%. Greenland Technologies (NASDAQ:GTEC) -16%. Aurinia Pharmaceuticals (NASDAQ:AUPH) -14% after filing mixed shelf offering. Longeveron (NASDAQ:LGVN) -12%. Mammoth Energy Services (NASDAQ:TUSK) -10%. Cerence (NA...
Amryt Pharma (NASDAQ:AMYT) announces the cancellation of admission of its ordinary shares to trading on AIM and intends to continue listing ADSs on Nasdaq. The AIM delisting will take effect at 7:00 a.m. on 11 January 2022. Following the delisting, the Company's ADSs will remain lis...
Amryt Pharma. (AMYT) Q3 2021 Results Earnings Conference Call November 03, 2021, 08:30 AM ET Company Participants Simon Loughrey - Group Financial Controller Dr. Joe Wiley - CEO Rory Nealon - CFO and COO Mark Sumeray - Chief Medical Officer Sheila Frame - President, Americas Conference Call P...
The following slide deck was published by Amryt Pharma in conjunction with their 2021 Q3 earnings call. For further details see: Amryt Pharma 2021 Q3 - Results - Earnings Call Presentation
Amryt Pharma (NASDAQ:AMYT): Q3 GAAP EPS of -$0.07. Revenue of $56.52M (+14.6% Y/Y) Press Release "Given the continued strong performance of the Company’s commercial products, the board is today reaffirming revenue guidance for FY 2021 in the range of $220M - $225M which represents grow...
News, Short Squeeze, Breakout and More Instantly...
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland a...
Turnover at €2 billion 749 million, with growth of 13.6% over 2021 The European market remains at the center, with significant international development The distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare disease...
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3 , 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq...